fi nal concentration of 0.5 mM. After induction, cell cultures were incubated for 3 h at 37°C with shaking. Typical expression volumes were 500 ml per 1 liter fl ask. Cells were pelleted and stored at Ϫ 80°C until protein purifi cation.
Purifi cation of recombinant human apoA-II
The cell pellets were suspended in chitin binding buffer (B2: 20 mM Na-HEPES [pH 8.5] , 500 mM NaCl, 1 mM EDTA) and subjected to three 1 min cycles of probe sonication (Fisher model 550 sonic dismembrator) at maximum output on ice. Soluble and insoluble fractions were separated by centrifugation at 10,000 g for 30 min at 4°C. A chitin bead column (1 × 25 cm) was packed with chitin beads for a total bead volume of about 15 ml and prewashed with buffer B2. Thirty milliliters of the lysed cell supernatant was passed through the column by gravity, followed by a wash with 5 column volumes of buffer B2. On-column cleavage of the chitin-bound protein was initiated by exchanging the column buffer with buffer B3 (20 mM Na-HEPES [pH 8.5] , 500 mM NaCl, 40 mM DTT, 1 mM EDTA). After overnight incubation at 4°C, the liquid phase was eluted from the column and dialyzed against 1× His binding buffer (20 mM Tris-HCl [pH 7.9], 5 mM imidazole, 500 mM NaCl). The fi nal volume was typically 15 ml. To remove residual uncleaved fusion protein and free intein-CBD fragments (which are his-tagged), the column eluate was passed through a nickel chelating column. The fl ow-through fraction containing purifi ed apoA-II was dialyzed against stardard tris buffer (STB) (10 mM Tris [pH 8.2] , 150 mM NaCl, 1 mM EDTA, 0.2% NaN 3 ) for further use.
Mass spectrometry analysis
Protein mass detection was carried out on an Applied Biosystems-Sciex QStar® XL mass spectrometer equipped with an ion spray source and a quadrapole time-of-fl ight dual analyzer. Intact proteins were separated on a capillary HPLC system (Agilent 1100) connected in-line with the mass spectrometer to remove any contaminants in the samples before the mass detection. A capillary C18 column (0.5 mm i.d. × 5 cm length, 300 Å particle size) (Grace Deerfi eld, IL) was used in HPLC separations with a solvent gradient of acetonitrile from 2% to 60% at a fl ow rate of 8 µl/min over 40 min. The gradient was generated using a solvent A (0.1% formic acid and 2% acetonitrile in water) and a solvent B (0.075% formic acid and 2% water in acetonitrile). The protein samples were solubilized in 0.1% TFA, and 30 pmol were injected in a 1 µl volume. Protein mass detection was determined using the Baysian protein reconstruct tool in the BioAnalyst suite of the Analyst QS software (Applied Biosystems).
Circular dichroism analysis
Proteins were freshly dialyzed against 20 mM phosphate buffer (pH 7.4), and relative concentration was determined by the Markwell-Lowry method ( 33 ) . Proteins were diluted to 150 g/ml, and spectra were collected in a 1 mm cell as an average of three accumulations. The scans were from 250 to 190 nm at 50 nm/min with a 0.5 nm step size and 0.5 s response. The bandwidth was set to 1 mm, and slit width was 500 m. To confi rm the accuracy of dilution, protein concentration was verifi ed by A280, and mean residual ellipticity was calculated based on this value as described by Woody ( 34 ) using 113.0 as the mean residual weight for apoA-II. Fractional helical content was calculated using the formula of Chen et al. ( 35 ) and the mean residual ellipticity at 222 nm. Each experiment was repeated on two independent protein preparations. The guanidine-HCl (Gnd-HCl) denaturation experiments were performed as in ( 36 ) . Midpoints of denaturation (D 1/2 ) were calculated by fi tting the experimental data points with sigmoidal curves generated by a four-parameter logistic Overexpression of human apoA-II in mice yielded different, and in many cases opposite, results in terms of plasma lipoprotein profi le, cholesterol effl ux effi ciency, and atherosclerosis development (reviewed in References 16, [28] [29] [30] . The applicability of these studies to human disease is signifi cantly complicated by the fundamentally different lipid metabolism of rodents versus humans and by major differences in regulation and structure of their apoA-II.
Another factor that has impeded our understanding of human apoA-II structure and function is the lack of an effi cient recombinant apoA-II expression system capable of producing large quantities of pure wild-type and variant proteins. Such a tool would greatly facilitate the in vitro study of human apoA-II structure and its interaction with human enzymes, lipoproteins, and cell lines. Similarly, recombinant murine apoA-II variants could be useful for in vivo infusion studies in mice. An Escherichia coli expression system that used a glutathione-S-transferase fusion protein and thrombin cleavage to liberate the fi nal apoA-II peptide was reported in the 1990s; however, its low effi ciency necessitated large-scale fermentation for reasonable protein yields ( 31 ) . Here, we report an E. coli expression system capable of producing highly pure human apoA-II in standard research lab-scale culture conditions. This system features a self-cleaving intein-apoA-II fusion protein and redundant affi nity purifi cation tags yielding mature human apoA-II. This recombinant apoA-II is shown to be structurally and functionally comparable to human plasma isolated apoA-II.
MATERIALS AND METHODS
Isopropyl ␤ -D-1-thiogalactopyranoside (IPTG) was obtained from Fisher. BL21(DE3) competent E. coli cells were purchased from Agilent Technologies. Dimyristoyl-phosphatidylcholine (DMPC) was obtained from Avanti Polar Lipids. Chitin resin and His binding resin were purchased from New England Biolabs and Novagen, respectively. The RAW264.7 macrophages used for the cholesterol effl ux assays were purchased from the American Type Culture Collection and were maintained in DMEM supplemented with 10% FBS and 10 g/ml gentamicin (all from Invitrogen). cAMP and gentamicin were purchased from Sigma. [1, [2] [3] H(N)]cholesterol ( 3 H-cholesterol) was obtained from Amersham Biosciences. All other reagents were of the highest quality available. Human plasma apoA-II was purifi ed as previously described ( 32 ) .
Circular dichroism measurements were made on a Jasco J-715 spectropolarimeter. The fl uorescence measurements were performed on a Photon Technology International Quantamaster spectrometer. A 1900CA Packard liquid scintillation analyzer was used to measure the radioactive cholesterol counts associated with the cholesterol effl ux assay. All absorbance measurements were made on an Amersham Biosciences Ultraspec 4000 UV/visible spectrophotometer.
Expression of recombinant human apoA-II
The apo-AII expression plasmid ( plate of labeled cells was washed with 3× PBS and incubated overnight in isopropanol to extract cellular lipids to determine the total radioactivity in the cells at T = 0 h. The isopropanol extract was dried under air, resolubilized in toluene, and counted. At the end of the 6 h incubation, a sample from each experimental well was fi ltered and counted. Each apolipoprotein was tested in triplicate wells, and the calculated percent effl ux was the average of these three wells. The reported percent effl ux is the media counts at the end of the 6 h incubation divided by the total internalized counts per well calculated using the control plate, with background effl ux to STB subtracted.
RESULTS

Summary of previous attempts
Our laboratory has developed bacterial expression protocols for numerous apolipoproteins using the PET system under control of the T7 promoter ( 38 ) . Our initial attempts at apoA-II expression involved the simple insertion of the apoA-II cDNA into our previous apoA-I construct ( 38 ) . Although we were able to detect expressed apoA-II in this system, the yield was unacceptably low. We then tested various combinations that included the addition of the apoA-I and apoA-II pro-segments, fusions with apoA-I, thioredoxin or glutathione S-transferase, and alternate equation. Native and fully denatured state ellipticities were measured at 0 and 6 M Gdn-HCl, respectively ( 37 ).
Liposome clearance assay
A turbid solution of DMPC multilamellar liposomes was generated on the day of the assay by combining N 2 -dried lipid with STB at 5 mg/ml using brief probe sonication. The liposomes and apolipoproteins, also in STB, were quickly mixed, yielding a fi nal DMPC to apoA-II mass ratio of 2.5:1, with fi nal apoA-II concentration of 0.17 mg/ml. A decrease in solution turbidity over time was monitored as a reduction in absorbance at 325 nm with measurements every 30 s for 10 min. The solution was maintained at 24.5°C, the gel/liquid crystalline transition temperature for DMPC, throughout the experiment with a thermostated water circulator. The data are expressed as a normalized optical density (OD) calculated by dividing the sample OD by the initial OD (OD 0 ). Two trials were performed on different days with independent preparations of protein.
Cholesterol effl ux assay
RAW264.7 cells were grown to 70% confl uency, washed twice with DMEM with 0.22% BSA (minimal media), and labeled with DMEM, 0.22% BSA, and 1.0 Ci/ml 3 H-cholesterol with or without 0.3 mM cAMP for 18 h. After labeling, cells were washed twice with minimal media and incubated with effl ux media (DMEM, 0.22% BSA, with or without 0.3 mM cAMP, and 1-10 g/ml apolipoprotein) for 6 h. At the start of the experiment, a control Fig. 1. pTWIN1 vector map showing the design of the apoA-II expression construct. Mature human apoA-II (blue) was subcloned into the pTWIN1 expression vector upstream of the T7 promoter with Mxe intein, a chitin binding domain, and a 6× histidine tag on its C terminus (green). To initiate transcription, a ATG codon was added to the N-terminus of the protein sequence. The site of intein-mediated endo-cleavage is indicated by a black arrow. The amino acid sequence of the translated apoA-II-intein fusion protein is reported: mature apoA-II (blue), modifi ed Mxe intein (green).
at University of Cincinnati, on November 11, 2013 www.jlr.org Downloaded from gel. Fig. 2B , lane 3 shows a prominent band at about 9 kDa corresponding to mature, monomeric apoA-II (8708 Da) and a faint ‫ف‬ 30 kDa band indicating leakage from the column of the residual intein/CBD fragment after cleavage of the fusion protein ( Fig. 2B , lane 2) . Further purifi cation of the eluate from the chitin column on a His-binding resin guaranteed complete removal of the cleaved fusion protein fragment, leaving highly pure (>95% by SDS-PAGE and mass spectrometric analyses) apoA-II ( Fig. 2B , lanes 4 and 5) . Overall, the yield of purifi ed apoA-II was approximately 12 mg per liter of bacterial culture.
Mass spectrometry
To verify the sequence of the expressed protein, we performed electrospray mass spectrometry on the recombinant protein and compared it with apoA-II purifi ed from human plasma. Fig. 3 (top) shows the mass spectrum of human plasma apoA-II eluted from a capillary reverse phase HPLC column at 18 min (see Experimental Procedures). Three prominent mass peaks were apparent: Peak A: 17,380; Peak B: 17,252; and Peak C: 17,124 Da. Human plasma apoA-II exists in solution primarily as a homodimer due to a disulfi de linkage mediated through Cys 6. The expected molecular mass is 17,414 Da. Although a very small peak near this value could be found by zooming in on this region in the mass spectrum, the most prominent peak (Peak A) exhibited a mass that was 33 Da lower. Peaks B and C were 128 and 256 Da, respectively, lower in mass than Peak A. This pattern was remarkably reproducible between independent plasma apoA-II isolations from our laboratory as well as others.
By contrast, the mass spectrum of recombinant apoA-II at the same HPLC retention time (18 min) exhibited a single major peak at 17,676 Da. Our recombinant expression systems using other promoters or host cell systems. Overall, these strategies met with little success, producing poor yields or no protein at all. However, attempts to express apoA-II in the pTWIN1 vector as a fusion with intein and the chitin binding domain ( Fig. 1 ) offered acceptable protein yields for the fi rst time. Furthermore, intein-mediated auto-cleavage allowed for effi cient release of the target human mature apoA-II from the fusion construct. Finally, the chitin binding domain (CBD), as well as our added C-terminal histidine-tag (His-tag), allowed for a simple two-step purifi cation strategy that yielded highly pure protein.
Expression of human apoA-II
The fi nal expression construct is shown in Fig. 1 .  pTWIN1 is an E. coli expression vector derived from pBR322 with a polylinker that allows the in-frame insertion of a target gene between two intein fusion proteins and a CBD. In our case, we elected to clone apoA-II upstream from the Mxe GyrA intein cassette, placing the intein and CBD at the apolipoprotein's C terminus. For added fl exibility in purifi cation, we added a 6× His-tag C-terminal to the CBD. Fig. 2A shows that activation of the T7 promoter by addition of IPTG stimulated expression of a ‫ف‬ 40 kDa protein (lane 3) that was consistent with the anticipated mass of 37 kDa for the fusion protein (27 kDa for the intein/CBD [manufacturer's documentation, New England Biolabs], 9 kDa for apoA-II, and 1 kDa for the His-tag). This band reacted with a polyclonal antibody for human apoA-II as determined by Western blot (not shown).
The apoA-II-intein/CBD fusion protein was purifi ed on a chitin column and auto-cleavage was induced oncolumn by addition of a thiol-reagent (DTT, 40 mM). After overnight incubation at 4°C, the liquid phase was eluted from the column and analyzed on a reducing SDS-PAGE 
Circular dichroism
To determine if the primary structure differences between human plasma and recombinant apoA-II noted above affected their secondary structures, we characterized them by far UV circular dichroism in the lipid-free state. Plasma apoA-II exhibited a characteristic spectrum for a helical protein with minima at 208 and 222 nm ( Fig. 4A ) . The average fractional helicity was calculated at about 40% in agreement with previous measurements ( 41 ) . Recombinant apoA-II exhibited a highly similar spectrum with a fractional helicity of about 38%. The denaturant-induced unfolding curves of plasma and recombinant apoA-II are shown in Fig. 4B . Midpoints of denaturation (D 1/2 ) for the two proteins (0.74 ± 0.05 M and 0.88 ± 0.03 M, respectively) were not significantly different. These data indicate that the overall secondary structural content and stability of the two proteins are quite similar despite the different the Nterminal amino acid.
Functional characterizations of recombinant apoA-II
We performed DMPC clearance assays, which determine the ability of a given protein to bind and reorganize multilamellar vesicles. Fig. 5 shows that DMPC liposomes incubated at 24.5°C in the absence of protein exhibited a high degree of light scattering due to the persistence of large multilamellar vesicles. Upon addition of human plasma apoA-II, the liposomes were rapidly cleared within 2-4 min. Under these conditions, apoA-II cleared lipid faster than apoA-I and apoA-IV ( 38 ) consistent with its well-known high hydrophobicity ( 42 ) . Recombinant apoA-II was similarly effi cient and even slightly more so across individual experiments, indicating that the sequence differences had little impact on the ability to bind and rearrange lipid bilayers. No signifi cant differences between human plasma and recombinant apoA-II liposome clearance kinetics were observed for different DMPC:protein ratios. After lipid clearance, the reaction mixtures were analyzed by nondenaturing gradient gel electrophoresis. Fig. 5c shows that both plasma and recombinant apoA-II generated two populations of lipoprotein particles, a major one at around 105 Å and a minor one at 96 Å, indicating that both forms can reorganize DMPC into similarly sized lipoproteins. We next assessed the ability of the two forms of apoA-II to promote cholesterol effl ux via the ATP-binding cassette transporter A1 (ABCA1) cell membrane transporter. We incubated the apoA-II proteins with RAW macrophages that had been stimulated to produce ABCA1 with exogenous cAMP ( 43 ) . In the absence of cAMP-stimulated ABCA1 expression, both recombinant and plasma apoA-II promoted little cholesterol release in the cell culture medium in 6 h ( Fig. 6 ). Upon addition of cAMP, both proteins promoted robust cholesterol effl ux with no statistically signifi cant differences between the two protein forms at all protein concentrations tested. We found no evidence that recombinant apoA-II produced in our system is structurally or functionally different from plasma purifi ed apoA-II, despite the differences in sequence at the N-terminus.
form contains an additional Met residue at the N-terminus (required to initiate translation), followed by the Gln normally at position 1 in mature plasma apoA-II after cleavage of its pre and pro sequence. With two extra Met residues per protein dimer, the predicted molecular mass of the recombinant form is 17,676 Da, in excellent agreement with the experimental value. This indicates that our recombinant apoA-II is of the correct sequence and is highly pure. In repeated SDS-PAGE analyses, we saw no evidence of monomeric apoA-II under the conditions of the experiment, indicating nearly 100% dimerization.
A comparison of the two mass spectra in Fig. 3 allowed for speculation on the complexity of the plasma apoA-II spectrum. When glutamine is present at the N-terminus, as in human plasma apoA-II, it can undergo cyclization to pyroglutamate with the release of NH 3 under acidic conditions ( Ϫ 17 Da) ( 39 ) . Dimeric apoA-II, containing two N-terminal Gln residues, would then be expected to lose 34 Da if both residues cyclize, explaining the near absence of the expected 17,414 Da mass for dimeric plasma apoA-II and the prevalence of Peak A (17,380 Da). Early attempts to sequence apoA-II by Edman degradation were unsuccessful, but treatment with pyrrolidonecarboxyl peptidase revealed the presence of an N-terminal pyroglutamic acid, which impedes the sequencing reaction ( 40 ) . This is supported by the fact that recombinant apoA-II was measured at its expected mass; the presence of the N-terminal Met precludes cyclization of the Gln at position 2. The explanations for Peaks B and C in plasma apoA-II are less straightforward but may involve the loss of the C-terminal Gln residues from each apoA-II strand ( ‫ف‬ 128 Da each), likely as a result of nonspecifi c exoproteases acting either in vivo or during the purifi cation. at University of Cincinnati, on November 11, 2013 www.jlr.org Downloaded from fermentation techniques to produce reasonable amounts of protein. Despite these issues, the expressed apoA-II exhibited a similar structure and ability to generate HDL-like particles as the human plasma form ( 31 ) . By contrast, the system described here is capable of producing milligram quantities of highly pure apoA-II that contains only an Nterminal Met residue. The purifi cation protocol is rapid, does not depend on expensive and temperamental proteases, and features two redundant affi nity chromatography options that result in highly pure protein. As demonstrated by circular dichroism spectroscopy, the secondary structure and stability of this recombinant apoA-II are similar to plasma isolated human apoA-II, as is its ability to reorganize phospholipid bilayers and promote ABCA1-mediated cholesterol effl ux.
DISCUSSION
The secretion of apoA-II from mammalian cells appears to be complex. Initially translated as a prepro form, the presegment is removed intracellularly, followed by possible O-linked glycosylation containing two or four sialic acid residues ( 44 ) . Upon cellular release, the pro-segment is quickly cleaved, and the protein is desialyated concomitant with cyclization of the N-terminal Gln (likely by an enzymatic process [ 39 ] ), producing the mature plasma form. Our mass spectrometry work suggests that additional clipping of the C-terminal Gln residues may also occur along this pathway. The reason for such a complicated secretion process is not clear but may be related to the efficient dimerization of the protein. Although Remaley et al. (45) have previously reported that O-linked glycosylation modifi es the lipid binding properties of apoA-II, further studies are needed to understand what, if any, signifi cance these posttranslational modifi cations have on apoA-II functionality or distribution in HDL particles. Despite this complexity during secretion, our mass spectrometric data on isolated plasma apoA-II provide no evidence that the circulating form is glycosylated or contains other mass additions, indicating that it is a reasonable candidate for bacterial expression.
One recombinant expression system for human apoA-II has been developed previously in bacteria ( 31 ) . Unfortunately, this protocol had several disadvantages. First, as far as we can determine, this construct is no longer available for use. Second, cleavage from the glutathione-S-transferase fusion protein required a long incubation with thrombin, which adds laborious steps and cost to the purifi cation. Third, the expression conditions required careful monitoring to prevent spontaneous degradation of the product after expression. Fourth, the produced apoA-II had three nonnative residues on its N-terminus. Finally, the expression yield was relatively low, requiring large-scale at University of Cincinnati, on November 11, 2013 www.jlr.org
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Although the price of chemically synthesized peptides is dropping consistently, our recombinant system is still highly cost effective because labor is the only expensive variable. Currently, the cost of 10 mg of recombinant protein can be estimated at about 200 US$. Thus, such a recombinant system is ideal for use in structural or functional studies requiring large quantities of apoA-II that can be mutated as needed. Potential applications include studies of the lipid-bound structure of apoA-II; the basis of its potential interactions with other HDL proteins, such as apoA-I; and exploration of putative functions, such as modulation of triglyceride lipase activity ( 27, 46 ) . at University of Cincinnati, on November 11, 2013 www.jlr.org Downloaded from
